索磷布韦维帕他韦片治疗慢性丙肝的临床效果研究

Study on the Clinical Effect of Sofosbuvir and Vipatavir Tablets in the Treatment of Chronic Hepatitis C

目的探讨索磷布韦维帕他韦片治疗慢性丙肝的临床效果。方法选择2018年10月至2019年12月在本院接受治疗76例慢性丙肝患者为研究对象,分为研究组和对照组,两组均为38例,对照组采用利巴韦林与干扰素α-2b联合治疗,研究组采用利巴韦林与索磷布韦维帕他韦片联合治疗,比较两组的疗效。结果研究组血小板(99.50±24.22)×10^(9)/L、外周血白细胞(3.43±0.32)×10^(9)/L、血红蛋白(113.47±11.25)g/L,相比对照组均更高(P<0.05);不良反应总发生率7.89%,相比对照组更低(P<0.05)。结论索磷布韦维帕他韦片与利巴韦林联合治疗慢性丙肝的效果显著,降低不良反应发生,抑制病毒复制。

Objective To explore the clinical effect of sofosbuvir vispatavir to blets in the treatment of chronic hepatitis C.Methods 76 patients with chronic hepatitis C who were treated in our hospital from October 2018 to December 2019 were selected as the research objects.They were divided into a study group and a control group.There were 38 cases in both groups.The control group was treated with ribavirin and interference in the combined treatment of alpha-2 b,the research group used ribavirin and sofosbuvir vepatavir to blets,then compared the efficacy of the two groups after the study.Results The platelets(99.50±24.22)×10^(9)/L,peripheral white blood cells(3.43±0.32)×10^(9)/L,and hemoglobin(113.47111.25)g/L in the study group were higher than those in the control group(P<0.05);The total incidence of adverse reactions was 7.89%,which was lower than that of the control group(P<0.05).Conclusion The combination of sofosbuvir vipatavir tablets and ribavirin is effective in treating chronic hepatitis C,reducing the occurrence of adverse reactions and inhibiting virus replication.